BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 17414645)

  • 1. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of osteoblastic bone metastases from prostate cancer.
    Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
    Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Logothetis CJ; Navone NM; Lin SH
    Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of bisphosphonates in prostate cancer.
    Oades GM; Coxon J; Colston KW
    Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approach to hormone-refractory prostate cancer.
    Saad F; Al Dejmah A; Perrotte P; McCormack M; BĂ©nard F; Valiquette L; Karakiewicz PI
    Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of bone metastasis in prostate cancer: clinical implications.
    Msaouel P; Pissimissis N; Halapas A; Koutsilieris M
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):341-55. PubMed ID: 18471791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.